About Abvance

  • Founded in 2016 around breakthrough research exclusively licensed from from Vanderbilt University

  • Company stage: pre-clinical
  • Strong IP portfolio
  • Rapid path to clinic and market for lead asset ABV100

  • Deeply experienced team in diabetes, metabolism, and drug development

Meet Our Team

David Maggs
David Maggs, MD FRCP
Chief Executive Officer and Co-founder

Dr. Maggs is a life science executive and endocrinologist with over 30 years of academic and industry experience. He graduated from Guys Hospital (UK), completed postgraduate studies at University of Nottingham, and held fellowship and faculty appointments at Yale School of Medicine. He is a Fellow of the Royal College of Physicians (UK) and holds an adjunct faculty position at UT Health, San Antonio. His industry experience includes leadership positions at Warner Lambert, Pfizer, Amylin Pharmaceuticals, GI Dynamics, Fractyl Health and, recently, Becton Dickinson. Over this span, he has worked on multiple pharmacological platforms (small molecule and peptide), and device programs, targeting rare and common diseases.

Alan Cherrington
Alan Cherrington, PhD
Co-founder and Scientific Advisor

Dr. Cherrington received his undergraduate degree in Biology from the University of New Brunswick and his PhD in Physiology from the University of Toronto. He currently holds the Jacquelyn A. Turner and Dr. Dorothy J.Turner Chair in Diabetes Research. Dr. Cherrington’s work over the years has defined the effects of various hormonal and neuronal factors on liver glucose metabolism. He is recognized worldwide as an authority in this area and is the recipient of multiple awards including the Banting Medal of the American Diabetes Association.

Steve Daly
Steve Daly
Chief Operating Officer

Steve has more than 30 years of experience in commercialization and product development, including 18 years in diabetes and metabolism. He has held executive and commercial leadership positions at companies working in the diabetes space including Modular Medical, Adocia, Halozyme, and Amylin Pharmaceuticals. Steve holds a Bachelor of Science degree in Business Administration from Northeastern University with MBA studies at the University of Florida.

Sam Collaudin
Sam Collaudin, PhD, MBA
Director, Scientific Affairs

Sam Collaudin was recently part of the business development team of Adocia. He is a consultant in business strategy for drug and device biotech companies specialized in diabetes. He held various board positions in healthcare, education and real-estate management organizations. He graduated with a PhD in Biology and Biomathematics from the ENS of Lyon and a junior MBA in biotech management from Grenoble Ecole de Management.

Soumitra Ghosh, PhD
Co-founder and Scientific Advisor

Soumitra Ghosh is a co-founder of Abvance Therapeutics, Avexegen Therapeutics, and Aquros Bio, biotech start-ups focused on diabetes, GI indications and urological disorders, respectively. His experience includes senior R&D leadership positions at Amylin Pharmaceuticals, Bristol Myers Squibb and MitoKor, where he led research programs for the development of small molecule, peptide and protein-based drug candidates for the treatment of metabolic diseases and CNS disorders. He received his MS and Ph.D. degrees in Chemistry from the Indian Institute of Technology and the University of Chicago and conducted his post-doctoral work at the Rockefeller University.

Scientific Board of Advisors

Bruce Bode MD
Bruce Bode, MD

Atlanta Diabetes Associates
Clinical Associate Professor, Emory University GA

john buse
John Buse, MD

Chief, Division of Endocrinology
University of North Carolina

Zan Fleming, MD

Executive Chairman & Founder of Kinexum, Exsulin, Tolerion
Former FDA official

Thomas Pieber, MD
Professor of Medicine
Chair, Division of Endocrinology and Diabetology
Medical University of Graz
William H. Polonsky, PhD, CDCES

President and Co-Founder
Behavioral Diabetes Institute

Stephen Smith, MD

Chief Scientific Officer
AdventHealth Orlando Research Services